Overview A Study of Olaratumab in Soft Tissue Sarcoma Status: Completed Trial end date: 2016-04-01 Target enrollment: Participant gender: Summary The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin. Phase: Phase 1/Phase 2 Details Lead Sponsor: Eli Lilly and CompanyTreatments: DexrazoxaneDoxorubicinLiposomal doxorubicinOlaratumabRazoxane